Research

Source MS Trust:  People with relapsing remitting MS starting early treatment with a disease modifying drug have a lower risk of developing secondary progressive MS, according to a study of medical records.

Source Medical News Today: A type of immune cell that migrates from the gut to the brain appears to reduce inflammation in multiple sclerosis, according to recent research.

Source AJMC: For patients with multiple sclerosis (MS), upper extremity (UE) impairment is not uncommon. Although patients across MS types report impaired UE function, patients with primary progressive MS (PPMS) tend to have a higher prevalence of UE dysfunction and greater impairment. A new study compared ocrelizumab with placebo in patients with PPMS to examine the effects

Source Medicalxpress:  For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression, according to a study published online Jan. 7 in JAMA Neurology. Yvonne Naegelin, M.D., from the University of Basel in Switzerland, and colleagues conducted a retrospective cohort study using data from patients with

Source Neurology Advisor: Increased levels of physical activity may lead to decreased vascular risk profiles in patients with multiple sclerosis, according to a literature review published in Multiple Sclerosis and Related Disorders. Researchers in this review searched for published articles in 5 major databases for studies involving physical activity, sedentary lifestyles, or exercise training and the impact these